These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25045284)

  • 1. Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes.
    Ahmadi H; Daneshmand S
    Patient Relat Outcome Meas; 2014; 5():63-70. PubMed ID: 25045284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
    Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
    Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
    Schulman C; Irani J; Aapro M
    BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
    Kim HS; Freedland SJ
    Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S; Puntus T
    Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
    Wolff JM; Abrahamsson PA; Irani J; da Silva FC
    BJU Int; 2014 Oct; 114(4):476-83. PubMed ID: 24433259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogenic side effects of androgen deprivation therapy.
    Guise TA; Oefelein MG; Eastham JA; Cookson MS; Higano CS; Smith MR
    Rev Urol; 2007; 9(4):163-80. PubMed ID: 18231613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Joseph JS; Lam V; Patel MI
    Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.
    Hershman DL; Unger JM; Wright JD; Ramsey S; Till C; Tangen CM; Barlow WE; Blanke C; Thompson IM; Hussain M
    JAMA Oncol; 2016 Apr; 2(4):453-61. PubMed ID: 26720308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
    Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
    BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues.
    Bagrodia A; Diblasio CJ; Wake RW; Derweesh IH
    Indian J Urol; 2009 Apr; 25(2):169-76. PubMed ID: 19672340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary role of androgen deprivation therapy for prostate cancer.
    Pagliarulo V; Bracarda S; Eisenberger MA; Mottet N; Schröder FH; Sternberg CN; Studer UE
    Eur Urol; 2012 Jan; 61(1):11-25. PubMed ID: 21871711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of hot flashes in men with prostate cancer being treated with androgen deprivation therapy.
    Alekshun TJ; Patterson SG
    Support Cancer Ther; 2006 Oct; 4(1):30-7. PubMed ID: 18632464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review.
    Edmunds K; Tuffaha H; Scuffham P; Galvão DA; Newton RU
    Support Care Cancer; 2020 Dec; 28(12):5661-5671. PubMed ID: 32699997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.